“My doctor talked to me about the risks and benefits of GLIVEC. I chose to restart GLIVEC therapy and not to give up.”
Patients who end adjuvant therapy and subsequently experience recurrence now have advanced disease. They need to know:
- GLIVEC therapy may be restarted until disease progression or intolerance1,3
- In a clinical trial, GLIVEC provided nearly 6 times the overall survival in advanced KIT+ GIST (57 months with GLIVEC vs 10 months before the GLIVEC era)4,5
- Surgical options may be appropriate in the advanced disease patient population3,6
Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.
References: 1. Glivec® (imatinib) summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited. 2. Sutent® (sunitinib malate) summary of product characteristics. Sandwich, Kent, UK: Pfizer Ltd. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed September 21, 2016. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 4. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-625. 5. Verweij J, Casali PG, Zalcberg J, et al; for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials Group. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134. 6. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):ii21-ii-26.